[go: up one dir, main page]

GB9105245D0 - Binding molecules - Google Patents

Binding molecules

Info

Publication number
GB9105245D0
GB9105245D0 GB919105245A GB9105245A GB9105245D0 GB 9105245 D0 GB9105245 D0 GB 9105245D0 GB 919105245 A GB919105245 A GB 919105245A GB 9105245 A GB9105245 A GB 9105245A GB 9105245 D0 GB9105245 D0 GB 9105245D0
Authority
GB
United Kingdom
Prior art keywords
binding molecules
molecules
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB919105245A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lynxvale Ltd
Original Assignee
Lynxvale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lynxvale Ltd filed Critical Lynxvale Ltd
Priority to GB919105245A priority Critical patent/GB9105245D0/en
Publication of GB9105245D0 publication Critical patent/GB9105245D0/en
Priority to CA 2105980 priority patent/CA2105980A1/en
Priority to EP19920906335 priority patent/EP0575407A1/en
Priority to PCT/GB1992/000445 priority patent/WO1992016562A1/en
Priority to JP4505594A priority patent/JPH06510659A/en
Pending legal-status Critical Current

Links

GB919105245A 1991-03-12 1991-03-12 Binding molecules Pending GB9105245D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB919105245A GB9105245D0 (en) 1991-03-12 1991-03-12 Binding molecules
CA 2105980 CA2105980A1 (en) 1991-03-12 1992-03-12 Humanised antibodies having modified allotypic determinants
EP19920906335 EP0575407A1 (en) 1991-03-12 1992-03-12 Humanised antibodies having modified allotypic determinants
PCT/GB1992/000445 WO1992016562A1 (en) 1991-03-12 1992-03-12 Humanised antibodies having modified allotypic determinants
JP4505594A JPH06510659A (en) 1991-03-12 1992-03-12 Humanized antibodies with altered allotypic determinants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919105245A GB9105245D0 (en) 1991-03-12 1991-03-12 Binding molecules

Publications (1)

Publication Number Publication Date
GB9105245D0 true GB9105245D0 (en) 1991-04-24

Family

ID=10691455

Family Applications (1)

Application Number Title Priority Date Filing Date
GB919105245A Pending GB9105245D0 (en) 1991-03-12 1991-03-12 Binding molecules

Country Status (5)

Country Link
EP (1) EP0575407A1 (en)
JP (1) JPH06510659A (en)
CA (1) CA2105980A1 (en)
GB (1) GB9105245D0 (en)
WO (1) WO1992016562A1 (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
GB9316989D0 (en) * 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
ES2590912T3 (en) 1997-12-08 2016-11-24 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immunotherapy and general immune system stimulation
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DE60025832T2 (en) 1999-08-09 2006-08-31 Emd Lexigen Research Center Corp., Billerica MULTIPLE CYTOKINE ANTIBODIES COMPLEX
GB9925490D0 (en) * 1999-10-28 1999-12-29 Univ Cambridge Tech Binding molecules and treatment and screening methods
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
CN1406249B (en) 2000-02-11 2010-06-16 默克专利股份有限公司 Increased circulating half-life of antibody-based fusion proteins
PT1294401E (en) 2000-06-29 2007-11-09 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
RU2003129528A (en) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) METHOD FOR EXPRESSION OF PROTEINS CONTAINING AN ANTIBODY HYBRID ISOTYPE AS A COMPONENT
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CN100503639C (en) 2001-05-03 2009-06-24 默克专利有限公司 Recombinant tumor specific antibody and use thereof
EP2354791A1 (en) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
PT1572748E (en) 2002-12-17 2010-09-28 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006524039A (en) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド Identification and production of antibody containing mutant Fc region and use thereof
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
BRPI0418286A (en) 2003-12-30 2007-05-02 Merck Patent Gmbh il-7 fusion proteins
KR20060124656A (en) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 Fc-erythropoietin fusion protein with improved pharmacokinetics
ATE437184T1 (en) * 2004-01-12 2009-08-15 Applied Molecular Evolution VARIANTS OF THE FC REGION
WO2005070967A2 (en) 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
US7521542B2 (en) 2004-05-10 2009-04-21 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
DK2213683T3 (en) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT Fc REGIONS
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
CN102746404B (en) 2004-11-12 2016-01-20 赞科股份有限公司 To FcRn in conjunction with reformed Fc variant
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CN101072793B (en) 2004-12-09 2012-06-20 默克专利有限公司 Il-7 variants with reduced immunogenicity
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
JP5838021B2 (en) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド Covalently bonded diabody and its use
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
PL1919503T3 (en) 2005-08-10 2015-04-30 Macrogenics Inc Identification and engineering of antibodies with variant fc regions and methods of using same
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
JP4860703B2 (en) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド Optimized anti-CD30 antibody
CN101351475B (en) 2005-12-30 2013-05-15 默克专利有限公司 Interleukin-12p40 variants with improved stability
DK2270050T3 (en) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19 antibodies with reduced immunogenicity
ES2489646T3 (en) 2006-05-26 2014-09-02 Macrogenics, Inc. Humanized antibodies specific to Fc gamma RIIB and its methods of use
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
PT2029173T (en) 2006-06-26 2016-11-02 Macrogenics Inc Fc riib-specific antibodies and methods of use thereof
HRP20140331T1 (en) 2006-08-14 2014-05-09 Xencor, Inc. OPTIMIZED CD19 DIRECTED ANTIBODIES
JP5562031B2 (en) 2006-09-18 2014-07-30 ゼンコー・インコーポレイテッド Optimized antibody targeting HM1.24
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
WO2009151717A2 (en) 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
WO2009117030A2 (en) 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
HRP20150279T1 (en) 2007-12-26 2015-05-08 Xencor, Inc. Fc variants with altered binding to fcrn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
PT2247304T (en) 2008-04-02 2016-08-29 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2775291A1 (en) * 2009-09-24 2011-03-31 Xbiotech, Inc. Methods, compositions, and kits for reducing anti-antibody responses
TR201804897T4 (en) 2009-10-07 2018-06-21 Macrogenics Inc POLYPEPTIDES CONTAINING FC REGION WITH ADVANCED EFFECTOR FUNCTION DUE TO CHANGES OF FUCOSILATION SIZE AND METHODS FOR THEIR USE
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CN103154025B (en) 2010-08-02 2015-07-01 宏观基因有限公司 Covalent diabodies and uses thereof
JP6145088B2 (en) 2011-05-21 2017-06-07 マクロジェニクス，インコーポレーテッド Deimmunized serum binding domain and its use to extend serum half-life
PE20150361A1 (en) 2012-07-13 2015-03-14 Roche Glycart Ag ANTI-VEGF / ANTI-ANG-2 BISPECIFIC ANTIBODIES AND THEIR USE IN THE TREATMENT OF EYE VASCULAR DISEASES
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
EP2968520B1 (en) 2013-03-14 2021-05-12 MacroGenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (en) 2013-08-09 2018-03-26 Макродженікс, Інк. SPECIFIC MONOVALENT Fc-DIATELY CONNECTING BACKGROUND OF THE CD32B AND CD79b AND ITS APPLICATION
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
SG11201702544WA (en) 2014-09-29 2017-04-27 Univ Duke Bispecific molecules comprising an hiv-1 envelope targeting arm
US10961311B2 (en) 2016-04-15 2021-03-30 Macrogenics, Inc. B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
WO2020154475A1 (en) 2019-01-23 2020-07-30 Molecular Templates, Inc. Proteins comprising modified immunoglobulin variable light chains

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2216126B (en) * 1988-02-12 1992-06-03 Medical Res Council Antibodies to the antigen campath-1

Also Published As

Publication number Publication date
EP0575407A1 (en) 1993-12-29
CA2105980A1 (en) 1992-09-13
WO1992016562A1 (en) 1992-10-01
JPH06510659A (en) 1994-12-01

Similar Documents

Publication Publication Date Title
GB9105245D0 (en) Binding molecules
GB9316989D0 (en) Binding molecules
GB9225453D0 (en) Binding proteins
GB9016299D0 (en) Binding substances
AU671148C (en) Binding element
ZA937445B (en) Binding element
GB9209562D0 (en) Binding machines
GB9027767D0 (en) Binding substances
GB9210608D0 (en) Binding system
GB9105074D0 (en) Improvements in binding
GB9421412D0 (en) Binding
GB2274429B (en) Book binding
GB9125582D0 (en) Binding molecules 2
GB9125579D0 (en) Binding molecules 1
GB2281248B (en) Indicating binding times
GB2249524B (en) Book binding
GB9110549D0 (en) Binding substances
GB9104744D0 (en) Binding substances
GB9210120D0 (en) Binding molecules
GB9024503D0 (en) Binding substances
GB9212045D0 (en) Binding
GB9107227D0 (en) Clips
GB9120377D0 (en) Improved binding substances
GB9206372D0 (en) Binding substances
GB9122293D0 (en) Book